Flyer

International Journal of Drug Development and Research

  • ISSN: 0975-9344
  • Journal h-index: 51
  • Journal CiteScore: 46.50
  • Journal Impact Factor: 26.99
  • Average acceptance to publication time (5-7 days)
  • Average article processing time (30-45 days) Less than 5 volumes 30 days
    8 - 9 volumes 40 days
    10 and more volumes 45 days
Awards Nomination 20+ Million Readerbase
Indexed In
  • Genamics JournalSeek
  • China National Knowledge Infrastructure (CNKI)
  • CiteFactor
  • Scimago
  • Directory of Research Journal Indexing (DRJI)
  • OCLC- WorldCat
  • Publons
  • MIAR
  • University Grants Commission
  • Euro Pub
  • Google Scholar
  • J-Gate
  • SHERPA ROMEO
  • Secret Search Engine Labs
  • ResearchGate
  • International Committee of Medical Journal Editors (ICMJE)
Share This Page

Research Article - (2017) Volume 9, Issue 1

Invitro Anti-inflammatory Activity of Extracellular L-asparaginase from Soil Rhizosphere Fungus Aspergillus tamarii

Mahabal NS1 and Kaliwal BB2*

1Department of Biotechnology and Microbiology, Karnatak University, Dharwad, Karnataka, India

2Department of Microbiology, Davangere University, Shivagangotri, Davangere, Karnataka, India

*Corresponding Author:

Kaliwal BB
Department of Microbiology
Davangere University
Shivagangotri, Davangere, Karnataka, India
Tel: +919449069219 E-mail: b_kaliwal@yahoo.com

Received Date: February 23, 2017 Accepted Date: March 22, 2017 Published Date: March 24, 2017

Citation: Mahabal NS, Kaliwal BB (2017) Invitro Anti-inflammatory Activity of Extracellular L-asparaginase from Soil Rhizosphere Fungus Aspergillus tamarii. Int J Drug Dev & Res 9: 30-34

Visit for more related articles at International Journal of Drug Development and Research

Abstract

In recent years L-asparaginase has been gaining interest of researchers as it is a potential anti-tumor drug. It has also been reported that the enzyme also possesses anti-inflammatory property. That present investigation is an insight to the invitro anti-inflammatory property of L-asparaginase extracted from that fungus Aspergillus tamarii. The invitro assessment methods included albumin denaturation assay, proteinase inhibitory activity and membrane stabilization using Diclofenac sodium and Aspirin as standard drugs. In the present study, L-asparaginase (10 μg/ml to 50 μg/ml) was used as the test sample for anti-inflammatory tests. The results indicated that 50 μg/ml of l-asparaginase showed significant inhibition values. 52.38% of albumin denaturation, 46.87% of proteinase inhibition, 55.26% of haemolysis inhibition and 51.21% of inhibition of hypotonic induced haemolysis. The results indicate that that extracted L-asparaginase possesses anti-inflammatory property apart from being an anti-tumor drug.

Keywords

L-asparaginase; Enzyme activity; Anti-inflammatory activity

Introduction

Inflammation is a part of the complex biological response of vascular tissues to harmful stimuli, such as pathogens, damaged cells or irritants. It is a self-defence reaction in its first phase, hence regarded as the main therapeutic target and often, the best choice to treat the disease and alleviate the symptoms. It is a complex response that protects the host against tissue injury and microbial invasion. The redness, swelling, heat, pain, and loss of functions are considered as symptoms of inflammation. Prolonged inflammation contributes to the pathogenesis of many diseases such as asthma, arthritis, multiple sclerosis and even cancer [1,2]. Inflammation can be classified as acute and chronic based on the commencement time. Acute inflammation is the primary response of the body to injurious stimuli and is involved in vascular changes i.e., vasodilatation, increased capillary permeability and migration of leukocytes. Chronic inflammation is prolonged inflammation characterized by progressive destruction and retrieving of injured tissue from the inflammatory process [3,4]. The process of inflammatory response is mediated by a variety of signaling molecules produced by mast cells, macrophages, granulocytes, platelets, lymphocytes and complement activation factors. The activation of these immune cells can be obtained by the release of chemical mediators from injured tissue and migrating cells. According to Safayhi and Sailer [5] macrophage cells play an important role in inflammation through the release of inflammatory mediators such as biologically active amines (histamine, serotonin), proteins and peptides (hydrolytic enzymes, cytokines, growth factors, and antibodies), Reactive Oxygen Species (ROS) like superoxide anion, hydroperoxide, hydroxyl radicals, Reactive Nitrogen Species (RNS) and lipids (platelet activating factors and prostaglandins) involved in the immune response. Delayed macrophage enactment is to a great extent in charge of the pathology of intense and unending incendiary conditions. Likely, Interleukin (IL-1) and Tumor Necrosis Factor (TNF) are master incendiary cytokines involved in fever, irritation, tissue pulverization [6]. The generation and their natural impacts are firmly controlled through different mechanisms, including mitigating cytokines, solvent cytokine receptors or receptor enemy proteins to avert undesirable irritation and tissue damage [7]. The discovery of each chemically vary large group, so called non-steroidal anti-inflammatory drugs (NSAIDs) such as diclofenac and indomethacin, have emerged as the most commonly used anti-inflammatory agents, including the therapy of rheumatoid arthritis which creates a shield against COX-1 and COX-2 enzymes (which responsible for inflammation) but the side effect including gastrointestinal ulceration, bleeding, renal damage and platelet dysfunction [8,9].

Several sources of anti-inflammatory compounds have been studied, which include medicinal plants, bacteria and fungi. Potent component from halotolerant fungus Alternaria alternate has also been studied. Based on this background of a variety of anti-inflammatory compounds the present investigation focuses on the assessment of anti-inflammatory property of L-asparaginase by invitro methods.

Materials and Methods

Extraction of L-asparaginase

Production of L-asparaginase was done through Solid State Fermentation. The identified fungal strain BBKNM3 Aspergillus tamarii was grown on 10 g of the substrate is moistened with water and inoculated with 1 ml of spore suspension in a 250 ml conical flask. The flasks were incubated at 37 ± 2°C for 72 hrs. After incubation the fungal extract was obtained and centrifuged at 10,000 rpm for 10 mins at 4°C. This clear supernatant served as crude enzyme extract and was used in determining the enzyme activity. The enzyme was purified to 105.21 fold purity and further it was assessed for its properties. Further the enzyme activity of the extract was measured using direct Nesslerization test [10].

Assessment of invitro anti-inflammatory activity

Inhibition of albumin denaturation: The anti-inflammatory activity of L-asparaginase was studied using the inhibition of albumin denaturation [11]. The method included the test extract and 1% aqueous solution of bovine serum. pH of the reaction mixture was adjusted using 1 N HCl. The samples were incubated at 37°C for 20 mins and then heated at 50°C for 20 mins. The mixture was allowed to cool and the absorbance was measured at 660 nm. The experiment was performed in triplicates.

The Percentage inhibition of protein denaturation was calculated as follows:

Percentage inhibition=(Abs Control-Abs Sample)×100/ Abs control.

Anti-proteinase action: The purified L-asparaginase was studied for its anti-inflammatory activity by anti-proteinase action [12,13]. Briefly, 2 ml of the reaction mixture along with 0.06 mg trypsin, 1 ml of 20 mM Tris HCl buffer (pH 7.4) and 1 ml of enzyme of varying concentrations (100-500 μg/ml). All test tubes were incubated at 37°C for 5 mins and 1 ml of 0.8% (w/v) casein was added. After 20 mins of incubation, the reaction was stopped by adding 70% perchloric acid. The formed cloudy suspension was centrifuged and supernatant was collected. The absorbance of the supernatant was read at 210 nm against buffer blank. The experiment was carried out in triplicates.

The percentage inhibition of protein was calculated using the formula

Percentage inhibition=(Abs Control-Abs Sample)×100/Abs control.

Preparation of Human Red Blood Cell Suspension (HRBC): Blood was collected from healthy volunteer who has not received any Non-steroidal Anti Inflammatory Drugs (NSAID’s) two weeks prior to the experiment. The blood sample was centrifuged at 3000 rpm for 10 mins and washed with normal saline. The step was repeated thrice and the volume of blood was reconstituted with normal saline to 10% (v/v) suspension [14].

Heat induced hemolysis: The hemolysis test was performed according to the method of Shinde et al. [15] with a slight modification. Reaction mixture was prepared by adding 1 ml purified L-asparaginase, 1 ml of 10% RBC suspension. Control was prepared by adding saline and RBC suspension. The tubes were incubated at 55°C for 30 mins in water bath. The tubes were cooled and centrifuged at 2500 rpm for 5 mins and the supernatant was collected. Absorbance was measured at 560 nm. The experiment was conducted in triplicates.

The Percentage inhibition of Haemolysis was calculated as follows:

Percentage inhibition=(Abs control-Abs sample)×100/Abs control.

Hypotonicity-induced haemolysis: Haemolysis of HRBC suspension was tested by preparing test sample containing 1 ml L-asparaginase+1 ml phosphate buffer+2 ml hyposaline and 0.5 ml HRBC suspension. Diclofenac sodium was used as standard (50 μg/ ml). The reaction mixture was incubated at 37°C for 30 mins and centrifuged at 3000 rpm for 10 mins. Supernatant was collected and estimated spectrophotometrically at 560 nm [16].

The Percentage inhibition of Haemolysis was calculated as follows:

Percentage inhibition=(Abs control-Abs sample) × 100/Abs control.

Statistical Analysis

All the experimental data were carried in triplicates and expressed as means ± standard errors. The statistical analyses of the data were performed using one way ANNOVA variance SPSS version 20.0 software with advanced models (SPSS Japan, Tokyo, Japan). Differences between means were located using Tukey’s test (P<0.05).

Results and Discussion

In the present investigation of in vitro anti-inflammatory property of L-asparaginase the results indicate that as the concentration of L-asparaginase increase there is an increase in the activity of L-asparaginase. This directly indicates that the enzyme is dose dependent drug. The enzyme shows maximum inhibition of albumin denaturation at 50 μg/ml concentration (Table 1). Similarly 50 μg/ ml concentration is also effective for proteinase inhibition (Table 2), haemolysis inhibition (Tables 3 and 4). Inflammation is a complex biological response of vascular tissue to harmful stimuli, pathogens, irritants characterized by redness, warmth, swelling and pain [17]. Prolonged inflammation leads to the rheumatoid arthritis, atherosclerosis, hay fever, ischemic heart diseases [18-20].

Treatments Concentration of L-asparaginase (µg/ml) Absorbance at 660 nm % inhibition of protein denaturation
Control - 0.42 ± 0.02 -
L-asparaginase 10 0.35 ± 0.03 16.66
  20 0.31 ± 0.07 26.19
  30 0.29 ± 0.01 30.95
  40 0.24 ± 0.04 42.85
  50 0.20 ± 0.03 52.38
Aspirin 50 0.30 ± 0.01 28.57

Each value represents the mean ± SD; N=3.

Table 1: Effect of L-asparaginase on heat induced protein denaturation.

Treatments Concentration of L-asparaginase (µg/ml) Absorbance at 660 nm % inhibition of proteinase
Control - 0.32 ± 0.02 -
L-asparaginase 10 0.26 ± 0.07 18.75
  20 0.25 ± 0.03 21.87
  30 0.23 ± 0.04 28.12
  40 0.21 ± 0.03 34.37
  50 0.17 ± 0.03 46.87
Aspirin 50 0.28 ± 0.02 12.50

Each value represents the mean ± SD; N=3.

Table 2: Effect of L-asparaginase on proteinase inhibitory action.

Treatments Concentration of L-asparaginase (µg/ml) Absorbance at 560 nm % inhibition of haemolysis
Control - 0.38 ± 0.03 -
L-asparaginase 10 0.29 ± 0.01 23.68
  20 0.32 ± 0.02 15.78
  30 0.25 ± 0.04 34.21
  40 0.23 ± 0.01 39.47
  50 0.17 ± 0.07 55.26
Aspirin 50 0.28 ± 0.03 26.31

Each value represents the mean ± SD; N=3

Table 3: Effect of L-asparaginase on heat induced haemolysis of erythrocyte.

Treatments Concentration of L-asparaginase (µg/ml) Absorbance at 660 nm % inhibition of haemolysis
control   0.41 ± 0.03 -
L-asparaginase 10 0.34 ± 0.06 17.07
  20 0.31 ± 0.02 24.39
  30 0.30 ± 0.02 26.82
  40 0.25 ± 0.04 39.02
  50 0.20 ± 0.01 51.21
Diclofenac sodium 50 0.21 ± 0.03 48.78

Each value represents the mean ± SD; N=3; Significance p?0.05

Table 4: Effect of L-asparaginase on hypotonicity induced haemolysis of erythrocyte.

Inflammation is a common manifestation of infectious diseases like leprosy, tuberculosis, syphilis, asthma, inflammatory bowel syndrome, nephritis, vasculitis, celiac diseases, auto-immune diseases etc. [21] Denaturation of proteins is a well-documented cause of inflammation. Proteinases have been embroiled in joint responses. Neutrophils are known to be a wellspring of proteinase which conveys in their lysosomal granules numerous serine proteinases. It was beforehand detailed that leukocytes proteinase assume critical part in the improvement of tissue harm amid in fiery responses and noteworthy level of insurance was given by proteinase inhibitors [22] Some resarchers report that denaturation of protein is one of the reason for rheumatoid joint pain because of the generation of auto-antigens in certain rheumatic sicknesses. It might be cause to in vitro denaturation of proteins [23]. Mechanism of denaturation is involved in alteration of electrostatic force, hydrogen, hydrophobic and disulphide bonds. Several authors have shown anti-inflammatory drugs to show dose dependent ability to inhibit the thermally induced protein denaturation [24].

The extracts of anti-inflammatory sources may potentially hinder the arrival of lysosomal substance of neutrophils at the site of irritation. These neutrophils lysosomal constituents incorporate bactericidal chemicals and proteinases, which upon extracellular discharge bring on additional tissue irritation and harm [25]. This report includes the use of extracellular L-asparaginase extract from fungal source. Fungal L-asparaginase is well reported to have lesser immunological allergies as compared to bacterial L-asparaginase [26]. Karunakaran et al. [27] reported the fungus A. oryzae which exhibited anti-inflammatory activity in dose dependent manner. Zhu et al. [28] reported new cadinane-type sesquiterpenes and hypocreaterpenes A and B along with five known compounds from marine-derived fungus Hypocreales sp. showed moderate in vitro anti-inflammatory activity with average maximum inhibition (Emax) values of 10.22% and 26.46% at 1 μM, respectively. High anti-inflammatory activity of the compound asperlin from marine-derived fungus Aspergillus sp was reported by Lee et al. [29]. Belofsky et al. [30] reported that Oxepinamides isolated from tunicate fungi Acremonium sp. exhibited comparable higher activity than standard drugs. Remarkable in vitro anti-inflammatory activity was reported in comparision with M. gulliermondii and marine fungal extracts from N. crassa. Nijveldt et al. [31] and reported that some flavonoids and steroids compounds from Diptheracanthus prostatus are known to show significant anti-inflammatory activity by inhibiting the COX and LOX systems.

Conclusion

The present investigation concludes that L-asparaginase which is a potent anti-tumor drug, also possesses anti-inflammatory property. L-asparaginase from many bacterial sources have been reported and are widely used as potential anti-tumor drugs. Further, these drugs also have properties of anti-inflammation and also anti-bacterial. Bacterial originated drugs have allergic reaction on some users on long term usage. Added to this literature, the present study reveals that the source of the enzyme is a fungus, it can possibly cause lesser allergies and hence can be a potent drug.

Acknowledgements

The authors are thankful to the Department of Biotechnology (DBT), Ministry of Science and Technology, Government of India, New Delhi, for funding the Bioinformatics Infrastructure Facility Project (BT/BI/25/001/2006 VOL II date 05- 03-2012), The Interdisciplinary Program for Life Science Project (BT/PR/4555/ INF/22/126/2010 dated 30-09-2010), UGC-UPE fellowship and PG Department of Biotechnology and Microbiology, Karnatak University, Dharwad, for providing the necessary facilities for the research.

Conflict of Interest

The authors hereby declare that they have no conflict of interest.

18669

References

  1. Holick MF (1996) Vitamin D and bone health. Journal of Nutrition 126: 1159-1164.
  2. Gardner DG, Chen S, Glenn DJ (2013) “Vitamin D and the heart”, Am J Physiol Regul Integr Comp Physiol 305: 969-977
  3. Tamer G, Arik S, Tamer I, Coksert D (2011) “Relative vitamin D insufficiency in Hashimoto’s thyroiditis”, Thyroid vol. 2: 891-896.
  4. Chen Y, Du J, Liu T, Shi Y, Ge X, (2014) “MicroRNA-346 mediated Tumor Necrosis Factor α-induced down regulation of gut Epithelial Vitamin D receptor in inflammatory bowel diseases”. Inflamm Bowel Dis 20: 1910-1918.
  5. Schöttker B, Jorde R, Peasey A, Thorand B, Jansen EH, et.al. (2014) “Vitamin D and mortality: meta-analysis of individual participant data from a large consortium of cohort studies from Europe and the United States”. BMJ 348: 3656-3658.
  6. Lehmann B, Querings K, Reichrath J (2004) “Vitamin D and skin: new aspects of dermatology”. Exp Dermatol 13: 11-15.
  7. Armas LA, Dowell S, Akhter M, Duthuluru S, Huerter C, et al. (2007) Ultraviolet-B radiation increases serum 25-hydroxyvitamin D levels: the effect of UVB dose and skin color. J Am Acad Dermatol 57: 588-593.
  8. Tsiaras WG, Weinstock MA (2011) “Factors influencing vitamin D status”, Acta Dermato-enereologica. 91: 115-124.
  9. Lips P, van Schoor NM, de Jongh RT (2014) Diet, sun, and lifestyle as determinants of vitamin D status. Ann N Y Acad Sci 1317: 92-98.
  10. Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, et.al. (2011) Endocrine Society: Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 96: 1911-1930
  11. Okazaki R1, Ozono K, Fukumoto S, Inoue D, Yamauchi M, et al. (2016) Assessment criteria for vitamin D deficiency/insufficiency in Japan-proposal by an expert panel supported by Research Program of Intractable Diseases, Ministry of Health, Labour and Welfare, Japan, The Japanese Society for Bone and Mineral Research and The Japan Endocrine Society [Opinion].
  12. Witham MD, Francis G (2014) Vitamin D in older people. Reviews in Clinical Gerontology 24: 158–171
  13. Zittermann A, Prockop S (2014) “The role of vitamin D for cardiovascular disease and overall mortality”. Adv Exp Med Biol 810: 106-119.
  14. Millet P, Guilland JC, Fuchs F, Klepping J (1989) Nutrient intake and vitamin status of healthy French vegetarians and nonvegetarians. Am J Clin Nutr 50 :718-727.
  15. Baig JA, Sheikh SA, Islam I, Kumar MJ (2013) Vitamin D status among vegetarians and non-vegetarians. Ayub Med Coll Abbottabad 25: 152-155.
  16. Lowik MR, Schrijver J, Odink J, van den Berg H, Wedel M (1990) Long-term effects of a vegetarian diet on the nutritional status of elderly people (Dutch Nutrition Surveillance System J Am Coll Nutr 9 :600-609.
  17. Laskowska-Klita T, Chelchowska M, Ambroszkiewicz J, Gajewska J, Klemarczyk W (2011) The effect of vegetarian diet on selected essential nutrients in children. Med Wieku Rozwoj 15: 318-325.
  18. Carnevale V, Modoni S, Pileri M, Di Giorgio A, Chiodini I, et.al. (2001) “Longitudinal evaluation of vitamin D status in healthy subjects from southern Italy: seasonal and gender differences”. Osteoporosis Int 12: 1026-1030.
  19. Van Schoor NM, Knol DL, Deeg DJ, Peters FP, Heijboer AC, et al. (2014) “Longitudinal changes variations in serum 25-hydroxyvita min D levels in different age groups: results of the Longitudinal Aging Study Amsterdam” Osteoporos Int 25:1483-1491.
  20. Crowe FL, Steur M, Allen NE, Appleby PN, Travis RC, et al. (2011) Plasma concentrations of 25-hydroxyvitamin D in meat eaters, fish eaters, vegetarians and vegans: results from the EPIC-Oxford study. Public Health Nutr 14: 340-346
  21. MacLaughlin J, Holick MF (1985) Aging decreases the capacity of human skin to produce vitamin D3. J Clin Invest 76 :1536-1538.
  22. Institute of Medicine (2011) Dietary Reference Intakes for Calcium and Vitamin D. Washington, DC: Institute of Medicine of the National Academies
  23. Nowson CA, McGrath JJ, Ebeling PR, Hikerwal A, Daly RM, et al. (2012) Working Group of Australian and New Zealand Bone and Mineral Society, Endocrine Society of Australia and Osteoporosis Australia. “Vitamin D and health in adults in Australia and New Zealand: a position statement” Med J Aust 196: 686-697.
  24. Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, et al. (2011) “Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline”. J Clin Endocrinol Metab 96: 1911-1930.